

The Emerging Therapy of Tomorrow with Nanomedicine: Present Status

R Kumar

Citation

R Kumar. *The Emerging Therapy of Tomorrow with Nanomedicine: Present Status*. The Internet Journal of Neurology. 2007 Volume 10 Number 1.

Abstract

Nanomedicine is new concept in combining nanotechnology and medicine. Nanotherapeutics is the use of nanomedicine in therapy. The definition of nanomedicine require attention as the nanotechnology represents a cluster of technologies. This article outlines present development in nanomedicine and prospect in nanotherapeutics. Health and safety issues also are discussed.

Richard Feynman a nobel Laurete predicted the emergence of a new science called nanotechnology in 1959, as this deals with structure of one to one hundred nanometers in scale ¹. Nanotechnology is term used to define the products, processes and properties at the nano/micro scale that have resulted from the convergence of the physical, chemical and life sciences. National Nanotechnology Initiative (NNI) defines nanotechnology as research and development at the atomic, molecular or macromolecular levels in the sub-100nm range (0.1-100nm) create structure, devices, and system that have novel functional properties ^{2,3}. Definition of nanotechnology as proposed by Bawa and Colleagues ⁴. "The design; characterization, production and application of structures, devices and systems by controlled manipulation of size and shape at the nanometer scale (atomic, molecular and macromolecular scale) that produces structures, devices and systems with at least one novel / superior characteristic or property. Nanotechnology is not new technology for eg. protein vaccines some peptiders and viruses also molecular medicine and biotechnology may be considered nanotechnology ^{2,3}. Nanotechnology will have a profound impact on the future of medical practice.

Nanomedicine is a combination of nanotechnology and medicine and it provide new direction in medical diagnosis, monitering and treatment at the level of single molecules or molecular assemblies at the "nano" scale of about 100nm or less. Nanomedicine defined as "the monitoring, repair, construction, and control of human biological systems at the molecular level, using engineered nanodevices and nanostructures ⁵. Nanomedicine is the application of

nanoscale technologies to the practice of medicine. It is used for diagnosis, prevention and treatment of disease and to gain increased understanding of underlying disease mechanisms. Presently nanomedicine involves detection of particles, drug delivery system, emulsions, and carriers for delivering vaccines: and biomaterials with unusual properties and improved biocompatibility. Nanotechnology is also biomimicry i.e. to understand the natures solution towards biological system or to learn from nature ⁶. Potential of nanomedicine market: "The market of nanobiotechnology has existed for only a few years, but it is expected to exceed \$3 billion by 2008, reflecting on annual growth rate of 28%" ⁷. "By 2014, 16% of goods in health care and life sciences (by revenue) will incorporate emerging nanotechnologies" ².

NANOMEDICINE TECHNOLOGIES AND TECHNIQUES: IN PROCESS OF PATENT ,,,,,,

Biopharmaceutics: Drug delivery (Drug encapsulation, Functional drug carrier), Drug discovery. Implantable materials: Tissue repaired and replacement (Implant coatings, Tissues regeneration scaffolds), Structural implant materials (Bone repair, Bioresorbable materials, Smart materials). Implantable devices: Assessment and treatment devices (Implantable sensors, Implantable medical devices), Sensory aids (Retina implants, Cochlear implants). Surgical aids: Operating tools (Smart instrument, Surgical robots). Diagnostic tools: Genetic testing (Ultrasensitive labeling and detection technologies, High throughput arrays and multiple analyses), Imaging (Nanoparticle labels, Imaging devices), Understanding basic life processes. Areas of potential

development:

In the following areas of nanomedicine including drug delivery ^{14,15} :

- Synthesis and use of novel nanomaterials and nanostructures.
- Biomimetic nanostructures (synthetic products developed from and understanding of biologic systems).
- Devices and nanosensors for detection of diseases and pathogens (eg, polymerase chain reaction-coupled micro/nano-fluidic devices).
- Identification of novel biologic targets / receptors / ligands for imaging diagnosis, and therapy (eg, for cancers and for neurodegenerative and cardiovascular diseases).
- Theranostics – Construction of multifunctional biologic nanostructures, devices, and systems for diagnosis and combined drug delivery.
- Nanotechnology for tissue engineering, and regenerative medicine.
- Stimuli-sensitive nanodevices and physically targeted treatments.
- Miniaturized nanofluidic devices and systems that transport fluids more efficiently to the site of delivery.
- More efficient site-specific targeting by way of nanodrugs, resulting in with reduces systemic side effects and better patient compliance.
- Close-looped drug delivery nanodevices and implants containing sensors on the same chips.
- Microsurgical devices, molecular motors, or nanobots that are capable of navigating throughout the body to repair damaged sites, destroy tumors or viruses, and even perform gene therapy.

NANODEVICES AND CATEGORIES OF NANOMEDICINE

Quantum dots: Quantum dots are precisely design fluorophores whose emission is directly related to their size (Quantum-confinement). These colloidal semiconductors are

single crystals with absorption and emission properties ^{16,17} , can be used as noninvasive indicators of tumors ^{18,19} .

Fluorescence resonance energy transfer (FRET): FRET between a donor and an acceptor molecule provides qualitative information about distance and quantitative information about the kinetics of changes in distance ²⁰ . These sensor perform in living cells and when manipulated through genetic engineering permit visualization of a variety of uptake and transport processes eg. high capacity glucose transport pathway system was identified in the lumen of the endoplasmic reficulumn (ER) ²¹ .

Dendrimers: Dendrimers are major class of chemical polymer (in nanoscale) ²² in which the atoms are arranged in many branches and sub-branches radiating out from a central core ²³ eg. MRI contrast agent in nanobased drug delivery. Dendrimers also known as “artificial proteins” synthesized as nanostructure and they are distinguished by their precise nanoscale scaffolding and nanocontainers properties. These are emerging nanomedicine. Polyamidoamine a multipurpose dendrimer prototype suitable for use as a targeted, diagnostic and for controlled delivery of cancer therapies ^{23,24} .

Nano-liposomes: The lipid based nanosystems eg. Nanoemulsions, lipid-core micelles and small unilamellar vesicles. This is to improve drug solubility to minimise adverse effect and to improve efficacy – useful strategy in cancer treatment ²⁵ .

Other-Nanodevices / Nanostructures: Nanowires has potential in the treatment of parkinsonism and other neurodegenerative disorders ²⁶ . Micelles – self assembling nanosized colloidal particles used to improve solubility of various pharmaceutical and act as drug carriers ^{27,28} . Nanotubes – carbon nanostructures, Shvedova AA et al ²⁹ reported the unusual inflammatory and fibrogenic pulmonary responses to single walled carbon nanotubes in mice (inhaled form). The nanotubes retained their fluorescent and emissive properties inside the white blood cells ³⁰ . Nanobombs: Boundle of carbon nanotubes its shockwave kills the cancerous cells useful in breast cancer ³¹ .

Nanoparticles and nanodevices eg. Nanobiosensors and nanobiochips are being used to improve drug discovery and development. Drug targeting by using nanoparticle should reduce systemic toxicity, encapsulation and nanocarriers protect drugs from metabolism and from excretion. Drug diffusion through pore (in organic aluminium oxide

nanoporous filter) – a novel method of administering antiangiogenic and antioxidant drugs. In the treatment of proliferative vascular disease.

Treatment modalities: are in various stages of development³². The goal of nanomedicine use is comprehensive monitoring, repair and important of all human biologic systems. Therapeutics of nanomedicine or Nanotherapeutics – The use of nanomedicine in therapy – the main areas of nanotherapeutics are - drug therapy, genetherapy and immunotherapy. In drug therapy because of size reduction or encapsulation of drug particle the therapeutic potential of water insoluble and unstable drug improve and also facilitate the delivery of drugs (small molecules) across blood brain barrier³³. In genetherapy the DNA nanoparticle can deliver functional genes to correct genetic disorder such a haemophilia cyticfibrosis and muscular dystrophy³⁴.

Nanomedicine in chemotherapy as diagnostic agent, in treatment, and to assess the progress of therapy³⁵. Based on nanoparticle technology – a drug containing paclitaxel as albumin-bound particle (size of 100-200nm) in an injectable suspension form for the treatment of breast cancer. This overcome the problem of insolubility with paclitaxel³⁶ (see in box).

Figure 1

Box: Nanomedicines– Status

Product	Type of nanomaterial	Indication	Phase
VivaGel	Dendrimer	Topical microbicide for HIV	Phase – 3
MRX-952	Branching block copolymer self-assembled nanoparticulate formulation of irinotecan metabolite	Oncology	Preclinical
Abraxane	Paclitaxel-albumin Nanoparticle	Non-small cell lung cancer, breast cancer, others	On market
Cyclosetc amptothecin	Cyclodextrin nanoparticle	Metastatic solid tumors	IND field
TNT AntiEpCAM	Polymer-coated iron oxide	Solid tumors	Preclinical
Verigene platform	DNA-functionalized gold nanoparticles	Diagnostic	On market
INGN-401	Liposome	Metastatic lung cancer	Phase – 1
Combidex	Superparamagnetic iron oxide nanoparticle	Tumor imaging	NDA field

Abbreviations: IND, investigational new drug; NDA, new drug application.

Cardiovascular nanomedicine: The role of nanomedicine in cardiovascular area are in diagnosis, in evaluation of atherosclerotic diseases activity and in management of cardiovascular diseases. The nanocardioproduct and approaches promise to change the present medical strategy of “see and treat” to “detect and prevent”³⁷. A variety of imaging devices i.e. supramagnetic nanoparticles and perfluorocarbon nanoparticle emulsion, for noninvasive MRI³⁸. Nanosensors designed for measuring nitic oxide (NO)

level at molecular level in a single endothelial cell³⁹. The No nanosensors are porphyrinic molecular metals (specifically designed electrically conductive organic material) that can oxidize No selectively and generate a current proportional to its concentration with the use of No nanosensor “Real-time” detection is possible at the level of single cell or neuron. Hsieh PC et al⁴⁰ reported that the locally controlled intramyocardial delivery of platelet – derived growth factor (PDGF) with peptide nanofibers improve postinfarction ventricular function without pulmonary toxicity, and leads to long term improvement in cardiac function.

Neurologic nanomedicine: The role of nanomedicine in neurology is to investigate molecular, cellular and physiologic process^{41,42,43}. To promote functional regeneration of the nervous system⁴⁴. To facilitate the delivery of drugs across the blood brain barriers⁴⁵ and in neuroprotective strategies⁴⁶. Flurescent indicator protein for glutamate (FLIPE) – a nanosensor developed to monitor glutamate level inside and at the surface of living cell⁴⁷. This neurotransmitter, excitatory in nature influence all form of bahviour and influence learning and memory⁴⁸ also involved in the neurologic damage as in stroke and neurodegenerative disorders⁴⁹, to prevent excitotoxicity and spillover to other synapses its rapid removal from synaptic cleft is essential. Alzheimers disease (AD) is other target for diagnosis⁵⁰.

The role of nanomedicine in dermatology, to provide, state of art patient care. Gold nanoparticle, quantam dot and magnetic nanoparticles are used in nanoimaging. In noninvasing imaging of skin high resolution dermoscopy, microscopy and spectroscopy offer advance diagnostic and therapeutic modalities.

To increase the efficacy of anticancer drug and to reduce the toxic effect, a polymeric misceller and liposome based delivery system conjugated to tumor specific ligands have been studied^{51,52,53}. In prostatic tumor – the tumor cell overexpress transferring receptor and for targeting drug to tumor, ligand transferring has been investigated⁵⁴. For the treatment of a localize prostatic tumor the approach is direct intertumoral delivery of biodegradable nanoparticles, a controlled release formulation, providing sustained drug effect⁵⁵. The drugs intracellular adhesion molecular (ICAM-1) protect endothelial cell from oxidative damage by reactive oxygen species particle. ICAM-1 is a good target for

vascular immunotargeting of nanoparticle to the damage endothelium⁵⁶. Carbon nanostructure - Fullerenes could be potential drugs in future. In the treatment of neurodegenerative disorder like parkinsonism, multiple sclerosis and other disease that are associated with oxidative stress and damage. Fullerenes can be use an alternative to chelating agent. Fullerenes also known as bulky ball (cluster of carbon C 60)⁵⁷. Fullerenes are resistant to biochemical degradation within the body – produce less adverse effect, nanotechnology facilitate the drug delivery. “Pharmacies on a chip”⁵⁸ researcher at the Massachusetts institute of technology achieved a controlled release of drug from microchip. Poly (Lactic acid) microchip device were manufactured to contain 36 drug reservoir⁵⁹.

An immunosuppressant agent sirolimus was approved by FDA as a solid dose formulation in year 2000⁶⁰.

Health and safety issues – a large proportion of the atoms that make up a nanoparticles because of their small size, are exposed to the exterior of the particle and may participate in many chemical processes. It may lead to the adverse consequences due to exposure in to the environment.

Studies in human showed that deposition of nanoparticle in the lungs increases with decreasing particle size and the toxicity of inhaled insoluble nanomaterials increases with decreases particle size and increasing particle surface area⁶¹. Certain classes of nanoparticle could be responsible for destructive inflammatory processes in the lungs eg. carbon black nanoparticle may induce a type-II alveolar epithelial cell line to release pro-inflammatory mediators.

Nanotechnology changes the properties of substance eg. Carbon as fullerenes and nanotubes an attractive candidate for applications but also make them dangerous, when expose to environment. The measures for safety needs to be taken on environmental concern with the use of nanotechnology⁶². Nanomedicine have potential to cross blood brain barrier⁶³ may cause harm to the patient.

The verichip corporation has declared the availability of the world first and only patented, FDA – cleared radiofrequency identification implantable microchip⁶⁴, with this ethical question arises about patient own personal detail which is available to other⁶⁴. Privacy and confidentiality of the patients may be affected. Goldstein⁶⁵ state that by eg. 2016 “----- your doctor will be capable of scanning your entire genome within a few minutes”. The protection and maintenance of health information of the patient is the

ethical issue, and while using nanotechnology in medical field ensuring privacy and confidentiality is of utmost importance.

SUMMARY

A clear definition of nanotechnology is an issue that require attention. Nanotechnology represents a cluster of technologies with different characteristic and applications. Nanomedicine related applications are under development and this is a long process of converting nanomedicine in to commercially viable products. The ultimate goal of nanotherapeutic is comprehensive monitoring repair and improvement of all human biologic system. There is great concern over the environmental and health risk with the use of nanomedicine. The protection and maintenance of health information of the patients is the ethical issue and ensuring privacy & confidentiality is of utmost importance while using nanomedicine.

ADDRESS FOR CORRESPONDENCE

Dr. Rajiv Kumar, MD # 1156-B, Sector 32-B, Chandigarh, INDIA. e-mail: DRajiv.08@gmail.com

References

1. Feynman RP. "There's plenty of room at the bottom" Eng Sci (Caltech) 1960;23:22-36.
2. Report. Sizing nanotechnology's value chain. New York: Lux Research; 2004.
3. Wolf J, Paull R, Herbert P. The nanotech report. New York: Lux Capital; 2003.
4. Bawa R, Bawa SR, Maebius SB et al. Protecting new ideas and inventions in nanomedicine via patents. *Nanomedicine* 2005;1(2):150-8.
5. Freitas RA. What is nanomedicine? *Nanomedicine* 2005;1:2-9.
6. Report. Nanotech's "second nature" patents: implications for the global south. Ottawa (ON): ETC Group; 2005.
7. Nanobiotechnology, opportunities and technical analysis. San Mateo (CA): Front Line Strategic Consulting; 2003.
8. Regaled A. Nanotechnology patents surge as companies vie to stake claim. *Wall Str J* 2004 section A1.
9. Bawa R. Nanotechnology patenting in the US. *Nanotechnology Law Bus* 2004;1:31-50.
10. Bawa R. Nanotechnology patents and the US patent Office. *Small Times* 2004;4:1 P8.
11. Bawa R, Bawa SR, Maebius SB. The nanotechnology patent "gold rush". *J Intellectual Property Rights* 2005;10:426-33.
12. The nanotech land grab. *Corp. Leg Times* 2004;14:34.
13. Miller JC, Serrato R, Represas-Cardenas JM et al. *Handbook of nanotechnology business, policy and intellectual property law*. New York: Wiley;2004.
14. Webster P. *World nanobiotechnology market*. Frost & Sullivan; 2005.
15. Bawa R, Bawa SR. Protecting new inventions in nanomedicine. In: Wagner CG, editor. *Foresight, innovation, and strategy: towards a wiser future*. Bethesda (MD): World Future Society; 2005.p.31-44.

16. Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. *Science* 2005;307(5709):538-44.
17. Chan WCW. Bionanotechnology progress and advances. *Biol Blood Marrow Transplant* 2006;12:87-91.
18. Chen GY, Yao SQ. Lighting up cancer cells with "dots" *Lancet* 2004;364(9450):2001-3.
19. Melton L. Imaging: The big picture *Nature* 2005;437(7059):775-9.
20. Lee JH, Hwang KS, Park J et al. Immunoassay of prostate-specific antigen (PSA) using resonant frequency shift of piezoelectric nanomechanical microcantilever. *Biosens Bioelectron* 2005;20(10):2157-62.
21. Fehr M, Takanaga H, Ehrhardt DW et al. Evidence for high-capacity bi-directional glucose transport across the endoplasmic reticulum membrane by genetically encoded fluorescence resonance energy transfer nanosensors. *Mol Cell Biol* 2005;25(24):11102-12.
22. Yang H, Kao WJ. Dendrimers for pharmaceutical and biomedical applications. *J Biomater Sci Polym Ed* 2006;17(1-2):3-19.
23. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflection on the field *Adv Drug Deliv Rev* 2005;57(15):2106-29.
24. Tomalia DA, Reyna LA, Svenson S. Dendrimers multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. *Biochem Soc Trans* 2007;35:61-7.
25. Moghimi SM, Agarwal A. Lipid-based nanosystems and complexes in experimental and clinical therapeutics [editorial]. *Curr Drug Deliv* 2005;2(4):295.
26. Llinas RR, Walton K, Masayuki N et al. Neurovascular central nervous recording / stimulating system: using nanotechnology probes. *Journal of Nanoparticle Research* 2005;7(2-3):111-27.
27. Torchilin VP. Lipid-core micelles for targeted drug delivery. *Curr Drug Deliv* 2005;2(4):319-27.
28. Ambade AV, Savariar EN, Thayumanavan S. Dendrimers micelles for controlled drug release and targeted delivery. *Mol Pharm* 2005;2(4):264-72.
29. Shvedova AA, Kisin ER, Mercer R et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. *Am J Physiol Lung Cell Mol Physiol* 2005;289(5):698-708.
30. Cherukuri P, Bachilo SM, Litovsky SH et al. Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells. *Am J Chem Soc* 2004;126(48):15638-9.
31. Panchapakesan B, Lu S, Sivakumar K et al. Single-wall carbon nanotube nanobomb agents for killing breast cancer cells. *Nanobiotechnology* 2005;1:133-9.
32. Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, mesotetraphenylporphyrin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. *Eur J Pharm Biopharm* 2006;62(3):235-40.
33. Gelperina SE, Khalansky AS, Skidan IN et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. *Toxicol Lett* 2002;126:131-41.
34. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. *Drug Discov Today* 2003;8:1112-20.
35. Huang X, El-Sayed IH, Qian W et al. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. *Am J Chem Soc* 2006;128(6):2115-20.
36. Service RF. Nanotechnology takes aim at cancer. *Science* 2005;310:1134.
37. Liu P, Konstam MA, Force T. Highlights of the 2004 scientific sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004. *Am J Coll Cardiol* 2005;45(4):617-25.
38. Cyrus T, Winter PM, Caruthers SD et al. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. *Expert Rev Cardiovasc Ther* 2005;3(4):705-15.
39. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. *Am J Cardiol* 2005;96(7B):13i-14i [Epub Aug 8, 2005].
40. Hseih PC, MacGillivray C, Gannon J et al. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. *Circulation* 2006;114:637-644.
41. Moxon KA, Kalkhoran NM, Markert M et al. Nanostructured surface modification of ceramic-based microelectrodes to enhance biocompatibility for a direct brain-machine interface. *IEEE Trans Biomed Eng* 2004;51:881-9.
42. Vu TQ, Chowdhury S, Muni NJ et al. Activation of membrane receptors by a neurotransmitter conjugate designed for surface attachment. *Biomaterials* 2005;26:1895-903.
43. Dahan M, Levi S, Luccardini C et al. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. *Science* 2003;302:442-5.
44. Silva GA, Czeisler C, Niece KL et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. *Science* 2004;303:1352-5.
45. Gelperina SE, Khalansky AS, Skidan IN et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. *Toxicol Lett* 2002;126:131-41.
46. Dugan LL, Lovett EG, Quick KL et al. Fullerene-based antioxidants and neurodegenerative disorders. *Parkinsonism & Related Disorders* 2001;7:243-6.
47. Okumoto Sakiko, Looger Loren L, Micheva Kristina D et al. Detection of glutamate release from neurons by genetically encoded surface-displayed FRET nanosensors. *Proc Natl Acad Sci USA* 2005;102(24):8740-5.
48. Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. *Science* 2001;294:1030-8.
49. Rothstein JD. Excitotoxicity hypothesis. *Neurol* 1996;47:S19-26.
50. Ghribi O. The role of the endoplasmic reticulum in the accumulation of beta-amyloid peptide in Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. *J Am Chem Soc* 2005;127(7):2264-71.
51. Gade TP, Hassen W, Santos E et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. *Cancer Res* 2005;65:9080-8.
52. Bucur O, Ray S, Bucur MC et al. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. *Front Biosci* 2006;11:1549-68.
53. Wolf S, Mertens D, Pscherer A et al. Ala228 variant of trail receptor I affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. *Int J Cancer* 2006;118:1831-5.
54. Carraway RE, Hassan S, Cochrane DE. Polyphenolic antioxidants mimic the effects of 1,4-dihydropyridines on neurotensin receptor function in PC3 cells. *J Pharmacol Exp Ther* 2004;309:92-101.
55. Bondi ML, Craparo EF, Giammona G et al.

Nanostructured lipid carries-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. *Drug Deliv* 2007;14:61-7.

56. Muro S, Cui X, Gajewski C et al. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. *Am J Physiol Cell Physiol* 2003;285:C1339-47.

57. Wilson SR. Nanomedicine; fullerene and carbon nanotube biology. In: Osawa E, editor. *Perspectives in fullerene nanotechnology*. Norwell, MA: Kluwer Academic Publisher; 2002.

58. Sarget T. *The dance of molecular*. New York: Thunder's Mouth Press; 2006.

59. Gareth Hughes A. Nanostructure-mediated drug delivery. *Nanomedicine* 2005;1:22-30.

60. Jain KK. The role of nanotechnology in drug discovery. *Drug Discov Today* 2005;10(21):1435-42.

61. Barlow PG, Clouter-Barker A, Donaldson K et al. Carbon black nanoparticles induce type-II epithelial cells to release chemotaxins for alveolar macrophages. *Part Fibre Toxicol* 2005;2(1):11.

62. Bulls K. Monitoring complex new nanotech materials may be too much for the agency to handle. *MIT Technology Review* 2005.

63. Lockman PR. Nanoparticle technology for drug delivery across the blood brain barrier. *Drug Dev Ind Pharm* 2002;28(1):1-13.

64. Verichip Available at:
<http://www.verichipcorp.com/index.html>.

65. Goldstein AH. Nanomedicine's brave new world. 2005. Available at:
<http://www.salon.com/tech/feature/2005/11/28/nanomedicine/print.html>.

Author Information

Rajiv Kumar, M.D.

Reader, Deptt. of Pharmacology, Govt. Medical College & Hospital